Normax Biomed and Oyster Venture Partners Join Forces to secure investment of €30,000,000 in first modular Vax Factory for rapid mRNA vaccine manufacturing in Wallonia, Belgium

Normax Biomed and Oyster Venture Partners Join Forces to Secure Investment of €30,000,000 in First Modular Vax Factory for Rapid mRNA Vaccine Manufacturing in Wallonia, Belgium

Normax is building a path for rapid growth of its global mRNA vaccine business in Wallonia, Belgium. With €300 million capital commitment from a cornerstone investor for research, development and manufacturing of mRNA vaccines

May 23, 2024, 12:00 PM Greenwich Mean Time (GMT) – NOT AN OFFER. SEE DISCLAIMER.

LIEGE, Belgium – Normax plans to invest €30,000,000 in its first Vax Factory in Liege after recently securing a €300 million pre-IPO capital commitment to help drive down the cost of vaccines, save more lives and support long-term sustainable pandemic preparedness. Normax who plans to use the €300 million capital commitment to scale up mRNA Vaccine R&D for Personalized Precision (n=1) Cancer Vaccines with Pandemic Preparedness for infectious disease, including H5N1 (bird flu) and the inevitable outbreak of “Disease-X”.

Normax mission is to become a global market leader in mRNA Vaccine R&D and distributed manufacturing. Walloia is a favoured location for expansion of global business services.

Until recently, the UK was considered a prime destination for many businesses looking to gain a foothold in the European market. However, Brexit has thrown these plans into uncertain waters and many organisations have had to reconsider their strategic growth plans. Walloia is one of Europe’s top locations for Investment in biotechnology business. Normax business investment in Wallonia enables freedom and flexibility to innovate and grow in the EI and in the global mRNA vaccine and therapeutics market.

Currently, leading COVID mRNA vaccine producers charge governments $8-$35 per dose. Normax plans to charge about $4 per dose for large scale delivery of safe and effective regulatory approved mRNA vaccines on advance purchase agreements. At Normax, the mission is to deliver Sustainable Business for Pandemic Preparedness.

“Our plans to build our first Vax Factory in Wallonia is a milestone in our ongoing journey of innovation and our growing footprint in EU. Liege has the potential for fast growth in a vibrant healthcare and biotech ecosystem.” says Peter A. Jensen, CEO and Chairman of Normax Biomed. “We believe Wallonia can enable Normax with a platform to deliver research and development of mRNA vaccines for TB, HIV and H5N1 whilst investing and deploying modular Normax Vax Factories, in up to ten locations. In the event of another public health emergency, we are also committed to delivering future mRNA vaccines in 100 days, to help ensure that COVID-19 is the last pandemic we will all suffer through. Pathogens are inevitable, but diseases are not.”

“With a very strong, visionary and experienced team, and a strategic cooperation in development with Bridge 2 Health and Wallonia, Normax is developing a revolutionary GMP process pipeline of personalized drug development technologies in combination with advanced artificial intelligence processing of patient data, for rapid delivery of mRNA vaccine immunotherapy for each cancer patient.” said Rupert Lewis, CEO at Oyster Venture Partners. “We are excited to support Normax Biomed in its mission and Oyster is committed to work with Normax investors to bring this transformative product with the potential to transform the lives of cancer patients in Belgium, and the EU.”

As well as research and development of the Universal Coronavirus mRNA Vaccine (UCV-mRNA), Normax is developing mRNA vaccine R&D and manufacturing strategies for TB and HIV, with the goal to end transmission of these deadly infectious diseases by 2050.

About 2.4 million people die every year from TB and HIV/AIDS, with a combined estimated global healthcare cost of more than $120 billion per year – a future potential monthly healthcare cost savings of $10 billion dollars and 200,000 lives saved.

With closure of €300 million pre-IPO capital investment commitment, Normax now plans an initial public offering (IPO) with a primary listing on the BX Swiss and a secondary listing on SIX Swiss Exchange with digital Normax subsidiary company listings on SIX Digital Exchange (SDX)

About Normax Biomed

The mission of Normax is to operate a mRNA immunotherapy sustainable business, with the ability to rapidly deliver vaccines in the event of an outbreak or pandemic: id.normaxbiomed.com

About Oyster Venture Partners

Oyster Venture Partners is a next generation corporate finance advisory firm supporting life science, healthcare and health-tech companies with their capital raising and sell-side/buy-side transactions. oysterventurepartners.com

Outbreaks are inevitable. Pandemics are not. Normax is on a mission to be a strategic partner in the global ecosystem for transformative research, development, and manufacture of safe and effective mRNA vaccines for global public health and pandemic preparedness and prevention.

Vax Factory by Normax. With a focus on partnership and open science, Normax is and investing in the future of mRNA Vaccines through shared R&D, scientific expertise, agility, and innovation, for the COVID-19 pandemic, infectious disease and long-term sustained pandemic preparedness and prevention. Our vision is to create a Freedom to Operate (FTO) ecosystem for mRNA Vaccines, where research and development can co-exist with an established Good Manufacturing Process (GMP) factory network at large-scale, small-scale and micro-scale.

How mRNA Vaccines Work. mRNA vaccine technology is a transformative new sector of the biopharmaceutical industry which has revolutionised vaccine development through increased speed, safety and cost-effective development leading to the first approved vaccines for the COVID-19 pandemic. It is estimated that over seven billion mRNA vaccines for COVID will be shipped by the end of 2022. mRNA technology allows researchers to fast-track the initial stages of vaccine research and development and thereby to produce safe and effective mRNA vaccines faster and more efficiently.

The story of Normax in 2 minutes

Media contact:

Berkeley Communications

+44 118 909 0909

normax@berkeleypr.com

Peter A. Jensen2024-05-18T13:53:11+00:00

Forward Looking Statements. No Offer or Solicitation. Professional Investors Only.Peter A. Jensen2023-02-03T11:00:00+00:00

Forward Looking Statements. No Offer or Solicitation. Professional Investors Only.

This website includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “will,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements about our beliefs and expectations and the estimated financial information and other projections contained herein. Such forward-looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of the businesses of Normax Biomed Ltd. are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those expressed or implied by such forward-looking statements. Please refer to the final prospectus of Normax Biomed Limited under “Risk Factors” therein, and other documents filed or to be filed with the London Stock Exchange and the Swiss Stock Exchange (SIX) by Normax Biomed Ltd. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Normax Biomed Ltd. undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

The information on this website shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. The information on this website shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the listing requirements of the London Stock Exchange and the Swiss Stock Exchange (SIX).

This website is directed only at, and provides information about products and services only available to, those who are Professional Clients or Eligible Counterparties as defined by the Financial Conduct Authority. The definitions can be found on the FCA website at www.fca.org.uk. This website is not intended to be accessed by any persons or entities domiciled in any jurisdiction where being treated as the types of clients stated would be contrary to local law.

Normax AbstractPeter A. Jensen2022-08-31T11:50:39+00:00

Normax Abstract

Normax Biomed Ltd (Normax) is based in Cork, Ireland, and London, England. Normax is in the business of mRNA vaccine Research, Development and Manufacturing. Normax has secured a €300,000,000 capital commitment from a $3.4Bn cornerstone institutional investor for development of mRNA Vaccines and Vax Factory Manufacturing for Transformative Social Impact on Infectious Disease and Pandemic Preparedness. Normax plans to drive down the cost of mRNA Vaccines to save more lives and to deliver sustainable returns for impact investors. Normax plans to deliver safe and effective mRNA vaccines at large scale for about $4 dollars per dose. Normax mRNA vaccine products in development include: (1) mRNA Vax Factory, (2) Universal Coronavirus mRNA Vaccine, (3) Tuberculosis mRNA Vaccine, (4) HIV mRNA Vaccine, (5) Malaria mRNA Vaccine, and (6) Disease-X mRNA Vaccine (e.g. within 100 days). Normax mission is to deliver competitive financial performance with transformative social impact. NOT AN OFFER TO INVEST.